CD39 and CD73, which are involved in the conversion of ATP to adenosine, can act on glioblastoma stem cells and immune cells through adenosine receptors (AR), affecting the secretion of inflammatory mediators, the differentiation and proliferation of immune cells, and enhancing the stemness characteristics of cancer cells, thereby intervening in immunosuppressive effects and pro-tumor functions (18). The gene discussed is ENTPD1; the disease is neoplasm.